A Phase 2/3 interventional study of CF101 and Placebo in Plaque Psoriasis, sponsored by Can-Fite BioPharma. Completed at 18 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-18.
Sponsored by Can-Fite BioPharma · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Psoriasis with a site in Bulgaria — 1 open to participants now, 4 under way, 4 of them phase 3. Psoriasis · Bulgaria.
Among the 46 studies in Psoriasis with a site in Bulgaria, this one is the 37th largest by enrollment, is one of 2 that started in 2011, is one of 2 in phase 2/3, and was the 9th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 46 studies in Psoriasis with a site in Bulgaria is open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Bulgaria, United States, Argentina and 22 more countries
Ages 40+
A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 32 · Phase 4 3
First in 2009; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 293 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 509 across the 46 interventional studies. Of the 42 that completed or were terminated, 28 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 46 have an industry lead sponsor. The 10 most frequent:
Can-Fite BioPharma is the lead sponsor of 22 studies on the registry; 5 are open to participants now.
Can-Fite BioPharma has 4 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 46 studies in Psoriasis with a site in Bulgaria, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.
Eligible patients will be randomly assigned to parallel dosing groups of CF101 2 mg or matching placebo tablets twice daily (BID) in a 1:1 ratio for the 16-week controlled treatment period. Approximately 94 patients will be assigned to each group.
Medication will be taken orally BID for 16 weeks in a double-blinded fashion. At the end of 16 weeks, all patients assigned to CF101 will continue CF101, while patients originally assigned to placebo will be reassigned to CF101.
Assessment of peripheral blood mononuclear cell (PBMC) adenosine A3 receptor (A3AR) expression at baseline and during treatment with CF101 in selected sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CF101 2mg oral tablets
Drug: CF101
Placebo oral tablets
Drug: Placebo
orally q12h
Also known as: IB-MECA
orally q12h
Also known as: Dummy pills
Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks
Achievement of PASI 75 indicates a 75% reduction in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)
Time frame: 12 weeks
Number of Subjects Achieving PGA of 0 or 1
PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe)
Time frame: 16 weeks
Numberof Patients Achieving Psoriasis Area and Severity (PASI) Score of 50 or 75
Achievement of PASI 50 or 75 indicates a 50% and 75% reduction respectively in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)
Time frame: 16 weeks
Nature and Frequency of Adverse Events
Assessment of safety of CF101 in this patient population by gathering adverse event data based on history, vital signs, physical examination, and laboratory data
Time frame: 32 weeks
| Milestone | CF101 2 mg | Placebo |
|---|---|---|
| Started | 145 | 148 |
| Completed | 125 | 135 |
| Not completed | 20 | 13 |
Achievement of PASI 75 indicates a 75% reduction in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)
| Participants | CF101 2 mg | Placebo |
|---|---|---|
| Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks | 12 | 10 |
PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe)
| participants | CF101 2 mg | Placebo |
|---|---|---|
| Number of Subjects Achieving PGA of 0 or 1 | 9 | 5 |
Achievement of PASI 50 or 75 indicates a 50% and 75% reduction respectively in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)
| participants | CF101 2 mg | Placebo |
|---|---|---|
| Numberof Patients Achieving Psoriasis Area and Severity (PASI) Score of 50 or 75 | 31 | 17 |
Assessment of safety of CF101 in this patient population by gathering adverse event data based on history, vital signs, physical examination, and laboratory data
| Participants | CF101 2 mg | Placebo |
|---|---|---|
| Any | 37 | 29 |
| Gastrointestinal disorders | 8 | 3 |
| Infections and infestations | 10 | 13 |
| Musculoskeletal and connective tissue disorders | 5 | 2 |
| Nervous system disorders | 6 | 0 |
| Renal and urinary disorders | 5 | 4 |
Collected over 16 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CF101 2 mg | — | 0/145 (0%) | 24/145 (16.6%) |
| Placebo | — | 0/148 (0%) | 15/148 (10.1%) |
| Event | CF101 2 mg | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 4/145 | 0/148 |
| Urinary tract infectionInfections and infestations | 2/145 | 4/148 |
| DiarrhoeaGastrointestinal disorders | 3/145 | 1/148 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/145 | 0/148 |
| NasopharyngitisInfections and infestations | 2/145 | 2/148 |
| Abdominal painGastrointestinal disorders | 2/145 | 1/148 |
| Dry mouthGastrointestinal disorders | 2/145 | 0/148 |
| NauseaGastrointestinal disorders | 2/145 | 0/148 |
| HaematuriaRenal and urinary disorders | 2/145 | 2/148 |
| ProteinuriaRenal and urinary disorders | 2/145 | 1/148 |
| Age, Continuous(years) | CF101 2mg | Placebo | Total |
|---|---|---|---|
| Mean | 48.3 ± 13.57 | 50.0 ± 13.96 | 49.2 ± 13.77 |
| Sex: Female, Male(Participants) | CF101 2mg | Placebo | Total |
|---|---|---|---|
| Female | 54 | 53 | 107 |
| Male | 91 | 95 | 186 |
The record gives a start of Jul 2011, a primary completion of Mar 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2017, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CF101